Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
XLO Xilio Therapeutics
3.000
-0.010-0.33%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-- -256.370% -- -43.151% -- -105.355% -- -105.355%
ROE
-- -715.191% -- -48.450% -- -148.421% -- -148.421%
ROA
4.42% -51.496% -- -40.991% 46.55% -59.597% 46.55% -59.597%
Efficiency Ratios
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- 11.135% -- 10.779% -- 10.643% -- 10.643%
Total Assets to Common Equity
-- 123.513% -- 118.198% -- 117.598% -- 117.598%
Debt to Asset Ratio
-- 14.041% -- 12.281% -- 11.075% -- 11.075%
Current Ratio
56.87% 9.1732 -- 14.8128 1605.35% 15.8489 1605.35% 15.8489
Quick Ratio
58.87% 8.9707 -- 14.4752 1684.97% 15.4995 1684.97% 15.4995
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
CEO: Russo BCPS, Pharm.D, Pharm.D., Rene
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top